Final Thoughts on Recent Data Updates in MDS
Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.
EP: 1.Diagnosing Myelodysplastic Syndromes (MDS)
EP: 2.Risk Stratification of MDS
EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia
EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia
EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia
EP: 8.Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia
EP: 9.Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation
EP: 10.Treatment Approaches for Lower-Risk MDS With RAS Mutations
EP: 11.ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
EP: 12.Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
EP: 13.Imetelstat for Lower-Risk MDS: Data From the IMerge Trial
EP: 14.Oral HMAs in Lower-Risk MDS Treatment
EP: 15.IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS
EP: 16.Key Trials in the Treatment of Higher-Risk MDS
Now Viewing
EP: 17.Final Thoughts on Recent Data Updates in MDS
Related Videos
Related Content
